On September 28th, the 27th National Clinical Oncology Conference and the 2024 Annual Academic Meeting of the Chinese Society of Clinical Oncology (CSCO) kicked off in Xiamen, Fujian. This prestigious event, focused on clinical oncology in China, embraced the theme “Patient-Centered, Shared Future,” drawing top-tier experts and scholars from around the globe to discuss the latest advancements in cancer diagnosis and treatment.
Recent data from the National Cancer Center reveals that China reported around 4.82 million new cases of malignant tumors in 2022. The conference underscored the essential role that technological innovation and support play in the prevention and treatment of these diseases. Leading experts engaged in discussions surrounding prevalent conditions such as lung cancer and lymphoma, sharing cutting-edge treatment philosophies that are shaping the future of oncology research.
Lung cancer continues to be the most common and deadliest malignant tumor in China. However, with recent breakthroughs in targeted therapies and immunotherapies, remarkable improvements in patient survival rates and overall quality of life have been noted. Professor Zhou Caicun from the East Hospital of Tongji University pointed out that advancing lung cancer treatment requires collaborative efforts among hospital specialists, academic societies, and pharmaceutical companies.
Meanwhile, Professor Ma Jun from the Harbin Institute of Blood Diseases and Oncology highlighted significant advancements in the treatment of hematological tumors. Under the guidance of dedicated CSCO committees, innovative protocols for lymphoma treatment and the development of new drugs are emerging, leading to higher cure rates for lymphoma patients.
Li Bin, Vice President of Medical Affairs at Roche Pharmaceuticals China, expressed optimism for collaborative initiatives aimed at creating a high-quality platform for academic research exchange. He stressed the importance of harnessing innovative methods such as digital intelligence and precision medicine to propel the oncology field forward, ultimately enhancing patient outcomes.
Since its founding in 1997, the Chinese Society of Clinical Oncology (CSCO) has grown into one of the largest nonprofit oncology professional organizations in China. Its mission revolves around fostering academic exchange and technological progress in oncology, bridging domestic and international expertise to elevate standards of cancer prevention and treatment across the country.
This year’s conference featured specialized sessions that covered a broad spectrum of cancer types and treatment strategies, uniting experts from government agencies, R&D firms, medical institutions, and health economics to deliberate on pressing topics, including the development of international anti-cancer drugs and innovative pharmaceuticals emerging from within China.
